Patents Assigned to Georgia State University
-
Patent number: 11884961Abstract: Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.Type: GrantFiled: June 1, 2018Date of Patent: January 30, 2024Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Peng George Wang, Jing Song, Muhammed Shukkoor Kondengaden, Aishwarya Parameswaran
-
Patent number: 11801299Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.Type: GrantFiled: July 6, 2021Date of Patent: October 31, 2023Assignee: Georgia State University Research Foundation, Inc.Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
-
Patent number: 11738098Abstract: Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.Type: GrantFiled: October 12, 2020Date of Patent: August 29, 2023Assignee: Georgia State University Research Foundation, Inc.Inventors: Jenny Jie Yang, Zhiren Liu, Jie Jiang, Shenghui Xue, Jinjuan Qiao, Mani Salarian
-
Patent number: 11717551Abstract: Disclosed are compositions comprising Rhamnus prinoides (GESHO) extract or fragments thereof and methods of using Gesho extract for the inhibition of biofilm formation.Type: GrantFiled: May 7, 2019Date of Patent: August 8, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Mariya Campbell, Eric Gilbert
-
Patent number: 11708320Abstract: The present invention provides processes for the synthesis of organic azides, intermediates for the production thereof, and compositions related thereto.Type: GrantFiled: June 28, 2019Date of Patent: July 25, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventor: Hao Xu
-
Patent number: 11685711Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.Type: GrantFiled: August 9, 2018Date of Patent: June 27, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Ladie Kimberly c. De La Cruz, Xingyue Ji, Zhixiang Pan, Binghe Wang
-
Publication number: 20230105108Abstract: Compounds and methods for use to treat a bacterial infection caused by, for example, gram positive bacteria, gram negative bacteria, and/or mycobacteria are provided herein. Also provided herein are compounds and methods for use in potentiating the effect of an antibiotic in the treatment of a bacterial infection. Pharmaceutical compositions including the compounds as described herein are also provided.Type: ApplicationFiled: December 18, 2020Publication date: April 6, 2023Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Binghe WANG, David W. BOYKIN, Arvind KUMAR, Mengyuan ZHU, Manjusha ROY CHOUDHURY, Bingchen YU
-
Patent number: 11607458Abstract: Disclosed herein is a chemical delivery system having: i) a cargo compound comprising a first reactive moiety covalently bonded to a first enrichment moiety and a tethered cargo moiety, wherein the first reactive moiety is bonded to the tethered cargo moiety via a cleavable linker; and ii) a trigger compound comprising a second reactive moiety covalently bonded to a second enrichment moiety and a cargo-releasing moiety. The first enrichment moiety and the second enrichment moiety cause an increase in concentration of the cargo compound and the concentration of the trigger compound at a target site, causing a bimolecular reaction between the first reactive moiety and the second reactive moiety to form a cyclization precursor compound. The cargo moiety is then released from the cyclization precursor compound in a unimolecular cyclization reaction. Methods for treating conditions such as cancer, inflammatory conditions, and infections with the chemical delivery systems are also described.Type: GrantFiled: October 25, 2018Date of Patent: March 21, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Binghe Wang, Yueqin Zheng, Xingyue Ji, Robert Emuobonuvie Aghoghovbia
-
Patent number: 11597845Abstract: A coating for conversion of formaldehyde to carbon dioxide includes an alcohol/aldehyde oxidase and a formate oxidase immobilized on a solid particulate support; and a latex binder.Type: GrantFiled: June 29, 2018Date of Patent: March 7, 2023Assignees: DOW GLOBAL TECHNOLOGIES LLC, ROHM AND HAAS COMPANY, GEORGIA TECH RESEARCH CORPORATION, GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: John Anderson Roper, III, Sudhakar Balijepalli, Paul Doll, Andreas S. Bommarius, Christopher W. Jones, Christopher R. Murdock, John M. Robbins, Akihiro Nomura, Bettina R. Bommarius, Adam Holewinski, Giovanni Gadda
-
Patent number: 11576960Abstract: Disclosed are vaccines capable of achieving protection against RSV while avoiding vaccine-enhanced disease (VED). In particular, vaccine constructs have been molecularly designed and genetically engineered to comprise RSV fusion (F) protein displayed on the surface of a particle, such as a virus-like particles (VLP) and low temperature-prepared split RSV. In some embodiments, the RSV F protein is in a pre-fusion F conformation. Also disclosed a variants and combinations of split RSV and RSV F DNA vaccine with pre-fusion F and enhanced efficacy. In addition, disclosed split RSV vaccines containing pre-fusion F conformation and combination adjuvants MPL and CpG.Type: GrantFiled: March 29, 2019Date of Patent: February 14, 2023Assignee: Georgia State University Research Foundation, Inc.Inventors: Sang-Moo Kang, Youri Lee, Eunju Ko, Young-Man Kwon, Ki-Hye Kim
-
Patent number: 11576609Abstract: The present disclosure relates to noninvasive methods for detecting liver fibrosis. Disclosed herein are noninvasive liver fibrosis detection methods that use Doppler Ultrasound devices and a physics-based machine learning method. Further disclosed herein are methods for detecting liver fibrosis in a subject by detecting and measuring the presence of a shift in the frequency of blood flow in the hepatic vein as compared to the frequency of blood flow in the portal vein.Type: GrantFiled: June 29, 2018Date of Patent: February 14, 2023Assignee: Georgia State University Research Foundation, Inc.Inventors: Yi Jiang, Hao Chen, Bin Zhang, Sergey Klimov
-
Patent number: 11572475Abstract: Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer.Type: GrantFiled: July 18, 2012Date of Patent: February 7, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Maged Henary, W. David Wilson
-
Patent number: 11517611Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can farther include other interleukins such as IL-1?, and IL-1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.Type: GrantFiled: April 23, 2020Date of Patent: December 6, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Andrew T. Gewirtz, Benyue Zhang
-
Patent number: 11517565Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is an bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.Type: GrantFiled: June 18, 2020Date of Patent: December 6, 2022Assignees: Emory University, Georgia State University Research Foundation, Inc.Inventors: Hyunsuk Shim, Suazette Reid Mooring, Renren Bai
-
Patent number: 11426471Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.Type: GrantFiled: September 9, 2020Date of Patent: August 30, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
-
Patent number: 11419954Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.Type: GrantFiled: September 9, 2020Date of Patent: August 23, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
-
Patent number: 11420994Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: GrantFiled: November 15, 2017Date of Patent: August 23, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Xingyue Ji, Zhixiang Pan
-
Patent number: 11377435Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.Type: GrantFiled: December 12, 2019Date of Patent: July 5, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Xingyue Ji
-
Patent number: 11376248Abstract: The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.Type: GrantFiled: December 20, 2019Date of Patent: July 5, 2022Assignee: Georgia State University Research Foundation, Inc.Inventor: Ming-Hui Zou
-
Publication number: 20220184200Abstract: Provided herein are virus-like particles and their uses for stimulating anti-pathogenic and anti-cancer immune responses.Type: ApplicationFiled: March 20, 2020Publication date: June 16, 2022Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Christopher F. BASLER, JoAnn M. TUFARIELLO, Lin WANG